Aim: - To evaluate the uptake and utility of the Advance Cancer MDT in Gippsland
Method: - Data was prospectively collected from September 2021 patients referred to the MDT and age, sex, cancer type, cancer stage, type clinical question addressed, clinical trials, precision oncology and palliative care were collected.
Results: -Total of 100 patients were discussed and median age was 69 (53-85), 55 % of patients were male and 45% were female. Colorectal, Breast, Lung and prostate cancer were the most frequently discussed among 21 different tumour types including cancer of unknown origin and suspected cancer. 93% of the patients had metastatic cancer 7% of the patients were at early stage. 31 Cases were discussed first time in the Gippsland MDT.
This MDT facilitated the management of the patients which included systemic chemotherapy in 39 patients, Palliative radiation in 12, symptom control in 10, Radiology review for the assessment of the treatment reasons or in diagnostic pathway in 29 patients. In 12 patients it was decided to stop the systemic treatment and recommended best supportive care only.
Role of the palliative care was discussed in 72 patients.
Clinical trials were discussed in 29 patients and 56 patients were deemed to be eligible for the precision oncology if one to be available.
Conclusion: - Advance Cancer MDT is a useful tool in the regional setting to provide evidence based optimal care. It has a potential to link de novo or recurrent cancer care in MDT setting. ADMDT can be used for wide purposes of care of the patient and has a potential to link the patient to clinical trials, palliative care and supportive care. It has potential to support the clinician to stop the futile management.